Selina Koch

DATA GRAPHICS | Discovery & Translation Brain shuttle technology is entering a new phase. A year after BioCentury mapped a field led by protein therapeutics, much of the activity is shifting toward using shuttles to deliver oligonucleotides to the bra... See more

uniQure reversal puts natural-history controls back in play for rare neuro FDA’s U-turn on AMT-130 gives Huntington’s and other rare disease sponsors a counterweight to CBER’s earlier rejection of external-control data FDA’s latest reversal on uniQure’s A... See more

Biogen finds Alzheimer’s path for tau ASO despite mixed data Low-dose diranersen outperformed higher doses on cognition, giving the company a Phase III path and a dose-response puzzle Biogen cannot yet explain why the low dose of its tau-targeting therapy... See more

Recursion’s Khan: AI will be judged by the medicines it makes AI’s clearest near-term gains, and its next frontier in drug development: The BioCentury Show As AI becomes embedded across biopharma, the label of techbio may lose some of its meaning. But eve... See more

Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul From muscarinic breakthroughs to next-gen psychedelics, what’s changing — and what isn’t — in the search for psychiatry medicines: The BioCentury Show With di... See more